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Studies of Parkinson’s disease (PD) have been
hindered by lack of access to affected human dopa-
minergic (DA) neurons. Here, we report generation
of induced pluripotent stem cells that carry the
p.G2019S mutation (G2019S-iPSCs) in the Leucine-
Rich Repeat Kinase-2 (LRRK2) gene, the most
common PD-related mutation, and their differentia-
tion into DA neurons. The high penetrance of the
LRRK2 mutation and its clinical resemblance to
sporadic PD suggest that these cells could provide
a valuable platform for disease analysis and drug
development. We found that DA neurons derived
from G2019S-iPSCs showed increased expression
of key oxidative stress-response genes and a-synu-
clein protein. The mutant neurons were also more
sensitive to caspase-3 activation and cell death
caused by exposure to stress agents, such as
hydrogen peroxide, MG-132, and 6-hydroxydop-
amine, than control DA neurons. This enhanced
stress sensitivity is consistent with existing under-
standing of early PD phenotypes and represents
a potential therapeutic target.
INTRODUCTION
Parkinson’s disease (PD) is one of the most common neurode-
generative disorders of aging, afflicting 0.9% of the population
65 years and older and increasing to 5.1% by the age of 85
(de Rijk et al., 2000). Although it is not well understood, the path-ogenesis of PD has been linked to both environmental and
genetic factors (Dawson and Dawson, 2003). A common auto-
somal dominant missense mutation, G2019S in the Leucine-
Rich Repeat Kinase 2 (LRRK2) gene, has previously been identi-
fied in 0.6%–1.6% and 2%–8% of sporadic and familial PD
cases, respectively (Hernandez et al., 2005; Nichols et al.,
2005; Paisan-Ruiz et al., 2005). The penetrance of the G2019S
mutation is age dependent, increasing from 17% at age 50 to
85% penetrance at age 70 (Kachergus et al., 2005). Clinical
symptoms associated with the G2019S mutation are nearly
indistinguishable from those of sporadic PD with pathologies
affecting bothmotor and nonmotor bodily functions. Histological
studies of postmortem brain tissue from PD patients, including
those with the p.G2019S LRRK2 mutation, showed cell loss in
the substantia nigra and formation of Lewy bodies, protein
aggregates containing a-synuclein (Baba et al., 1998; Ross
et al., 2006). While therapeutic drugs may treat some symptoms
of PD, curative therapies and methods to halt disease progres-
sion have yet to be developed. Moreover, although transgenic
animal and cell models expressing known PD-associated genes
have provided important insights into the disease (Betarbet et al.,
2002; Heo et al., 2010; Ng et al., 2009; Paisan-Ruiz et al., 2004;
Schu¨le et al., 2009), it has been difficult to demonstrate that
implicated mechanisms are also present in neurons from an
affected individual. iPSC-derived neurons from affected individ-
uals hold promise of providing a missing link between current
models and PD pathology.
Although derivation of iPSC lines from sporadic PD patients
has been reported (Park et al., 2008; Soldner et al., 2009), it is
not known whether PD iPSC–derived neurons exhibit PD pheno-
types and whether sporadic PD lines will demonstrate overt
phenotypes. Thus, proof of principle that iPSC lines may recapit-
ulate key phenotypes of PD may be most appropriately revealed
with monogenic mutations.Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 267
Cell Stem Cell
iPSC-Derived Neurons Model Parkinson’s DiseaseRESULTS
Generation and Characterization of PD-Derived iPSCs
A 60-year-old female patient, with early onset (48 years), typical
L-DOPA (L-3,4-dihydroxyphenylalanine)-responsive PD, and
homozygous for the p.G2019Smutation in the LRRK2 gene, con-
sented to a skin biopsy and iPSC derivation. After expansion of
the primary dermal fibroblast line (termed HUF6), cells were
transduced with retroviruses carrying three reprogramming
factors, OCT4, SOX2, and KLF4, as previously described (Taka-
hashi et al., 2007; Nakagawa et al., 2008). Approximately
2 months postinfection, three hESC-like colonies were picked
for propagation under standard human embryonic stem cell
(hESC) culture conditions. Two clones (6c1-iPSC and 6c3-
iPSC, collectively referred to as G2019S-iPSCs) were then
selected for detailed analysis. G2019S-iPSCs exhibited
morphology similar to hESCs, were alkaline phosphatase posi-
tive, and were immunoreactive for OCT4, NANOG, LIN28,
SSEA3, SSEA4, TRA1-60, and TRA1-81, while being negative
for SSEA1 (Figure 1A). iPSCs were successfully cultured in an
undifferentiated state for more than 30 passages (8 months).
G2019S-iPSCs were able to differentiate into cell types of all
three germ layers both spontaneously in vitro and in vivo (Figures
1B–1C and Movie S1 available online). Further analysis showed
that undifferentiated G2019S-iPSCswere hypomethylated at the
OCT4 and NANOG promoter regions compared to donor
fibroblasts and differentiated iPSCs, retained the missense
homozygous G2019Smutation, and maintained a normal karyo-
type (Figures 1D–1F). Gene-expression profiling showed that
undifferentiated and differentiated G2019S-iPSCs had a similar
expression pattern, as control iPSCs from a healthy adult human
female previously derived with four factors, including CMYC
(termed HUF5-iPSC) and H9 hESCs (Thomson et al., 1998)
(Figure S1). Importantly, RT-PCR analysis of all iPSC lines
showed complete silencing of exogenous factors after reprog-
ramming, and exogenous factors remained silent after 35 days
of in vitro-directed neuronal differentiation (Figure 1G). This sug-
gested that whether three or four reprogramming factors were
used, exogenous genes were silenced. Genomic DNA analysis
also confirmed that G2019S-iPSCs have integrated three re-
programming factors withoutCMYC (Figure 1H). Taken together,
these findings demonstrate that both undifferentiated and differ-
entiated G2019S-iPSCs are very similar to wild-type iPSCs and
hESCs in cell morphology, pluripotency markers, differentiation
potential, epigenetics, and gene-expression profile.
Directed Differentiation of iPSCs into Midbrain
Dopaminergic Neurons
Since PD is associated with degeneration of midbrain dopami-
nergic (mDA) neurons, we sought to determine if both normal
and PD iPSC lines, HUF5-iPSCs and G2019S-iPSCs, respec-
tively, could differentiate into mDA neurons in vitro. We followed
an established protocol, with modifications (Figure S2A), that
used a combination of small molecules and midbrain-selective
patterning factors, FGF8b (fibroblast growth factor 8 beta) and
SHH (sonic hedgehog), to direct human iPSC differentiation to
DA neurons (Chambers et al., 2009). During the course of differ-
entiation, iPSC lines generated numerous neural progenitor cells
(immunopositive for PAX6 and nestin) and, subsequently,268 Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc.neurons (immunopositive for doublecortin and b-III-tubulin,
data not shown). A significant number of these neurons also
expressed tyrosine hydroxylase (TH; rate-limiting enzyme in
synthesis of dopamine) (Figure 2A). Other markers consistent
with a midbrain phenotype were also present including forkhead
box A2 (FOXA2), orphan nuclear receptor (NURR1), paired-like
homeodomain transcription factor 3 (PITX3), and LRRK2
(Figures 2A and 2B). Orthodenticle homeobox 2 (OTX2) and cal-
bindin (CALB) were also expressed in a portion of TH-positive
neurons (Liang et al., 1996; Vernay et al., 2005) (Figure S2).
Notably, OTX2 expression in TH-positive cells appeared to be
most consistent with a ventral tegmental area (A10, VTA)
phenotype, as described in mouse brain (Di Salvio et al., 2010),
whereas FOXA2, NURR1, PITX3, and LRRK2 may play an
important role in development of midbrain neurons, specifically
substantia nigra pars compacta (A9, SNpc) subtype (Han et al.,
2008; Ichinose et al., 1999; Kittappa et al., 2007; Nunes
et al., 2003).
Quantification of mDA neurons was based on average cell
counts from three different clones of HUF5-iPSC, two clones
of G2019S-iPSC, and an hESC control (H9) line. We observed
that 97%–98% of neurons after 35 days of differentiation and
enrichment were positive for FOXA2, consistent with the FGF8/
SHH patterning environment. We also observed that a signifi-
cant, though minority, fraction of these cells (3.6%– 5%) also
differentiated into TH-expressing neurons within the course of
differentiation (Figure 2C). Colocalization of multiple midbrain-
specific markers with TH suggested that many iPSC-derived
neurons may be of an mDA phenotype, the cell type lost in PD
neurodegeneration.
We also observed properties that suggested that TH-positive
neurons derived from HUF5- and G2019S-iPSCs were mature.
First, the neurons expressed synaptotagmin-1 (SYT1), a protein
localized to synaptic vesicles (Figure 3A). Second, electrophysi-
ological recordings of these neurons 30–35 days after differenti-
ation demonstrated that they could fire action potentials (Figures
3B–3D). Approximately 60%of recorded cells fired action poten-
tials in response to depolarizing current injections (Table S1) and
showed spontaneous synaptic activities (Figure 3E). Third, these
DA neurons were able to synthesize and release dopamine in
response to stimulation with high potassium (Figure 3F). Col-
lectively, these results suggest that iPSC-derived neurons
produced by this protocol are sufficiently mature to be functional
and form spontaneously active neural networks in culture.
Characterization of iPSC-Derived Neurons
We next sought to characterize iPSC-derived neurons in more
detail. Thus, we directed iPSC differentiation into mDA neurons,
picked neuronal aggregates of approximately 100 cells (both
manually and after enzymatic treatment), and assayed for gene
expression at various time points (undifferentiated, 14, 35, 50,
and 55 days of differentiation) via microfluidic qPCR. Cluster
analysis of gene expression showed that samples correlated
primarily by stage of neuronal differentiation and demonstrated
expected expression patterns (Figure 4A). Undifferentiated
iPSC lines andH9 hESCs strongly expressed pluripotency genes
clustered together and had closest relatedness to 14 day
neurons, while 35, 50, and 55 day neurons expressed
neuronal-specific genes and grouped together on separate
Figure 1. Generation and Characterization of Human iPSCs Carrying a p.G2019S LRRK2 Mutation
(A) Progression of iPSC colony formation during reprogramming and subsequent expression of pluripotencymarkers: alkaline phosphatase (AP), OCT4, NANOG,
LIN28, SSEA3, TRA1-60, TRA1-81, SSEA4, and mostly negative expression for SSSEA1. Cell nuclei were counterstained with DAPI (blue). dpt, day post-trans-
duction; Scale bar, 100 mm.
(B) In vitro differentiation of G2019S-iPSCs to cells representative of each germ layer: a-fetoprotein (AFP, endoderm), b-III-tubulin (ectoderm), a-smooth muscle
actin and desmin (mesoderm), and VASA and STELLA (germ cell precursors). Also, neurons, beating cardiomyocytes, and pigmented cells are easily observed
under a phase microscope.
(C) In vivo (teratoma) differentiation of G2019S-iPSCs (clones 6c1 and 6c3) with evidence of all three germ layers: gut-like epithelium (endoderm), cartilage and
muscle (mesoderm), and neural-like tissues (ectoderm). Scale bar, 100 mm.
(D) Methylation analysis of OCT4 and NANOG promoters. Open and closed circles represent unmethylated and methylated CpG islands, respectively.
(E) Genomic DNA sequencing showing presence of homozygous p.G2019S mutation in dermal skin fibroblasts (HUF6) and G2019S-derived iPSCs, but not in
normal HUF5 skin fibroblasts or iPSCs.
(F) Spectral karyotyping (SKY) analysis of G2019S-iPSCs (clone 6c3-iPSCs).
(G) Gene expression of endogenous (En.) and exogenous (Ex.) reprogramming factors in iPSCs and differentiated 35 day neurons. HUF5-4F is a positive control,
and RNA was collected 3 days after virus transduction; HUF5 and HUF6 are nontransduced human dermal skin fibroblasts.
(H) PCR analysis of the iPSCs. 6c1- and 6c3-iPSCs (G2019S) have three integrated reprogramming factors without CMYC and 5c2- and 5c3-iPSCs have four
factors with cMYC.
See also Figure S1 and Movie S1 for more characterization of iPSCs.
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gested that the neuronal differentiation procedure follows
expected developmental pathways, provided credence to usingsmall-scale samples in RT-PCR analysis, and showed that these
iPSC-derived neuron gene-expression patterns bear similarity to
that of developing human fetal brain. Detailed analysis ofCell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 269
Figure 2. Directed Differentiation of iPSCs into Midbrain Dopaminergic Neurons
(A) Expression of midbrain dopaminergic (mDA) neuron markers, tyrosine hydroxylase (TH), FOXA2, PITX3, and NURR1 in iPSC-derived 30 to 35 day neurons.
Note the colocalization of FOXA, PITX3, and NURR1 with TH, characteristic of mDA neurons (arrows). NESTIN- and TUJ1-positive immunoreactivity also show
the presence of neurons. Scale bar, 50 mm.
(B) Expression of LRRK2 proteins in dopaminergic neurons. Scale bar, 10 mm.
(C) Quantification of the yield of mDA neurons, based on TH and FOXA2 colocalization, in 35 day neurons derived from H9, HUF5, and G2019S lines.
See also Figure S2 for more characterization of iPSC-derived neurons.
Cell Stem Cell
iPSC-Derived Neurons Model Parkinson’s Disease
270 Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc.
Figure 3. Differentiation of iPSCs into Functional DA Neurons
(A) Expression of synaptotagmin-1 (SYT1), a synaptic vesicle protein, in DA neurons generated from HUF5- and G2019S-iPSCs. Scale bar, 50 mm.
(B) Exemplar of electrophysiological recordings from cells with typical neuronal morphology, residing remotely from the cell clusters.
(C) Current clamp recordings of voltage deflections induced by injections of current of different amplitude (DIinj = 5 pA).
(D) Voltage clamp recordings of the net currents at various membrane potentials (80 to +20, DV = 10 mV, Vhold = 90 mV).
(E) Spontaneous synaptic activity of the neurons measured at 70 mV.
(F) HPLC measurements of total level of dopamine release from iPSC-derived neurons relative to TH protein expression. Data represent mean ± SEM (n = 2).
See also Table S1 for electrophysiological recordings of neurons.
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iPSC-Derived Neurons Model Parkinson’s Diseaserepresentative genes, such as LIN28, SNCA, HSPB1, and PAX6,
from a group of neurons and from single neurons verified cluster
analysis (Figures 4B–4E and Figures S3A–S3F). Note, however,
that a subset of markers presumed to be midbrain specific,primarily FOXA2 and PITX3, were not consistently expressed
during some stages of differentiation. This observation could
be because of analysis of subsets of neurons with unique
midbrain phenotypes or alternative subtypes. We observedCell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 271
Figure 4. Characterization of Human iPSC-Derived Neurons
(A) Gene expression analysis of HUF5- and G2019S-iPSC-derived neurons at various stages of in vitro differentiation. Cluster analysis of iPSCs and various
neuronal differentiation stages (14–55 days). Fe. brain, whole human fetal brain; red, high expression; green, low; black, zero.
(B) Quantitative RT-PCR analysis showing average expression of LIN28, a-synuclein (SNCA), heat shock 27kD protein 1 (HSPB1), and paired box gene 6 (PAX6) in
normal HUF5-iPSC- and G2019S-iPSC-derived neurons. Gene expression normalized to GAPDH, CENTB3, EEF1a, and CNNTB1 (based on a geometric mean)
by qBasePlus. Data represent mean ± SEM (n = 3–7 biological replicates per clone).
(C) Western analysis of human dermal fibroblasts (HDF), iPSCs, hESCs, and 60 day neurons derived from iPSCs and hESCs.
(D) Graphical representation of western blot performed in Figure 4F. Relative protein abundance was normalized to GAPDH. Error bars represent standard
deviation from two independent neuronal differentiation. *p < 0.05.
See also Figure S3 for RT-PCR analysis of iPSC-derived neurons.
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Engrailed-1 and -2, were often highly expressed.
To further characterize neurons generated, we manually
isolated 35 day single neurons and assayed for gene expression
using the same techniques mentioned above. 35 day HUF5-
iPSC- and G2019S-iPSC-derived single neurons self-clustered
together and correlated with other bulk neuronal samples,272 Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc.including human fetal brain (data not shown). Using direct
gene-to-gene comparison between G2019S- and HUF5-derived
neurons, the average expression of single neurons showed
similar relative gene expression pattern as neurons prepared in
bulk (Figures S3D and S3E). We also noticed that there was
a cell-to-cell variability in gene expression, consistent with the
fact that the neurons represent multiple stages of differentiation
Cell Stem Cell
iPSC-Derived Neurons Model Parkinson’s Diseaseand include both TH-positive and TH-negative neuronal
subtypes. In summary, data from small aggregates and from
single neurons demonstrated gene expression patterns indica-
tive of successful neural lineage determination and differentia-
tion into mature neurons though variation in gene expression
was observed.
Emergence of Disease-Related Phenotypes
in iPSC-Derived Neurons
Direct comparison between G2019S- and HUF5-iPSC-derived
neurons showed differential gene expression at various stages
of differentiation, some of which indicated differential steady-
state oxidative stress. Genes involved in oxidative stress
pathways such as HSPB1, NOX1, and MAOB were expressed
higher (3.7-fold for NOX1 and MAOB; 1.4-fold for HSPB1) at
day 35 in G2019S-iPSC-derived neurons than HUF5-iPSC-
derived neurons (Figure S3C). We noted that expression levels
of some other key oxidative stress response genes were also
slightly higher in G2019S-iPSC-derived neurons than HUF5-
iPSC-derived neurons at day 35, but not at day 50 and 55.
Accumulation of a-synuclein protein is also implicated in
LRRK2 gain-of-function mutations. a-Synuclein is a major
component of Lewy bodies, protein aggregates that form in
neurodegenerative disorders such as Lewy body disease,
Alzheimer’s disease, and PD (Bayer et al., 1999; Giasson et al.,
2006; Hashimoto and Masliah, 1999; Spillantini et al., 1998).
Previous studies demonstrated that overexpression of LRRK2
G2019S protein can lead to abnormal accumulation of a-synu-
clein, either as a direct consequence of phosphorylation of
SNCA protein by LRRK2 or indirectly through alterations in
kinase signaling leading to increased SNCA gene expression
or protein stabilization (Cookson, 2009).
We observed that a-synuclein protein was not detected by
western blot in HUF5 and G2019S (HUF6) dermal fibroblasts;
was only detectable at very low levels in undifferentiated
HUF5-iPSCs, G2019S-iPSCs, and H9-hESCs; and was
expressed at much higher levels in mature neurons (Figures 4C
and 4D). In comparison to HUF5-iPSC- and H9-hESC-derived
neurons, G2019S-iPSC-derived 60 day neurons showed a signif-
icant increase (3- to 8-fold) in monomeric a-synuclein protein
levels (p < 0.05, n = 2 independent differentiations with two repli-
cate wells per line in each experiment). Results also indicated
that, in these samples, there was no significant difference in
TH expression (Figure 4D), suggesting that higher a-synuclein
expression was not because of the presence of more TH-posi-
tive cells but instead correlated with genotype. Based on this
analysis, G2019S-iPSCs appeared to present at least a subset
of native PD-related phenotypes of increased indicators of
oxidative stress and a-synuclein accumulation even after
reprogramming to pluripotency and differentiation into dopami-
nergic neurons in vitro.
G2019S-iPSC-Derived DA Neurons Are Differentially
Susceptible to Peroxide-Induced Cell Death
Next, we compared susceptibility of H9-, HUF5-iPSC-, and
G2019S-iPSC-derived neurons to hydrogen peroxide (H2O2).
iPSC-derived neuronal clusters were transferred to 48-well
plates (five clusters per well). Following at least 2 days of
recovery, 35 day neurons were treated with various concentra-tions of H2O2 and visually evaluated after 24 or 48 hr in order
to establish a survival curve (Figure 5A). We found that, at
0–0.05 mM, most neurons survived after 24–48 hr of treatment
(n = 257 wells, three independent experiments). In contrast, at
0.1 – 1 mM, neurons progressively degenerated after 24–48 hr
(n = 230 wells), and at 5–50mM, there were no surviving neurons
at 24 hr (n = 36 wells). At 48 hr, cells were fixed and stained for
type III beta tubulin (Tuj1, a generic marker for neurons), TH,
and activated (or cleaved) form of caspase-3 (CASP3), an
apoptotic marker. Confocal imaging was used to score the
fraction of TH-positive or TH-negative neurons that were cola-
beled for CASP3. Apoptotic index was determined for three
independently derived clones of HUF5-iPSC (5c1, 5c2, and
5c3), two independently derived clones of G2019S-iPSC (6c1
and 6c3), and H9-derived DA neurons (Figures 5B and 5C and
Table S2). In some clones, experiments were independently
repeated to validate internal reproducibility. Based on two-way
analysis of variance (two-way ANOVA), the apparent increase
in cell death was not significant between all lines at different
H2O2 treatments. However, when ignoring treatment dosage,
we observed a significant effect of cell type [F(5,67) = 8.53,
p < 0.000003, n = 12–24 per cell line]. Duncan’s multiple-range
post-hoc analysis revealed that independent replicates of
G2019S-iPSC-derived DA neuron cultures had significantly
more cell death than both wild-type HUF5-iPSC- and H9-derived
DA neuron cultures. To determine if the effect of H2O2 was
specific to DA neurons, we also performed the same analysis
on TH-negative (TUJ1+) neurons. We observed that TH-negative
neurons were less susceptible to peroxide-induced cell death at
all concentrations tested, and there was no significant difference
between unaffected and diseased cell lines (Figures S4A and
S4B). These findings suggested that G2019S-iPSC-derived DA
neurons may be more susceptible to oxidative stress and
CASP3 activation than normal H9- and HUF5-iPSC-derived DA
neurons.
We also analyzed gene expression profiles of iPSC-derived
neurons via qPCR as in previous experiments but, this time,
following treatment of neurons with a sublethal dose (25 mM) of
H2O2 for 48 hr. Expression of some of the oxidative stress-
response genes, such as CASP9 and HSPA1A, was increased
in G2019S-iPSC-derived neurons relative to unaffected
H9- and HUF5-iPSC-derived neurons (Figure S4C). In particular,
HSPB1 (Heat Shock 27kDa Protein 1) expression was signifi-
cantly higher in G2019S-iPSC-derived neurons than normal
HUF5-iPSC-derived neurons (p = 0.009, n = 4); on the other
hand, expression of the neuronal genes, LRRK2 and Engrailed
2 (EN2), was lower in G2019S-iPSC-derived neurons than
HUF5- and H9-derived DA neurons (p = 0.04 and 0.07, respec-
tively, n = 4). Expression of SNCA (a-synuclein) in G2019S-
iPSC-derived neurons was also higher than in H9-derived
neurons (p = 0.07, 2-fold, n = 4) and slightly higher (no signifi-
cance, n = 4) than HUF5-iPSC-derived neurons.
We also sought to quantitate and verify potential effects of
H2O2 on differentiated neurons by western blotting. Data indi-
cated that in all treatments and stages of neuronal differentiation,
relative abundance of activated CASP3 expression in G2019S-
iPSC-derived neurons was higher than in HUF5-iPSC-derived
neurons (Figure 5D). Differences were most notable (2- to
3-fold) at 10 mM (36 day) and 25 mM (25 day) H2O2 treatments.Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 273
Figure 5. Effect of Hydrogen Peroxide on hESC- and iPSC-Derived DA Neurons
(A) Effect of H2O2 treatment on 35-day neurons after 24 and 48 hr. Survival rate from 1 to 48 hr was measured by observation under the phase-constrast
microscope and immunostaining for Tyrosine Hydroxylase (TH) after 48 hr. At least 7–21 wells from 3 independent experiments at each time point and concen-
tration within 0.01 - 1 mM range.
(B) Hydrogen Peroxide (H2O2) causes neuronal degeneration in vitro. Note presence of spontaneous and induced cell death, identified by activated (or cleaved)
form of caspase-3 (CASP3) immunofluorescence, at all concentrations. Arrows indicate the regression of neuronal axons after 0.1 mMH2O2 treatment. Scale bar,
100 mm.
(C) Quantification of cells double positive for TH and CASP3 in different clones of normal (wild-type) H9 andHUF5-iPSC versus disease G2019S-iPSC-derived DA
neurons in the treatment of various of H2O2 concentrations. Data represent mean ± SEM (n = 3–6 wells per clone, two independent experiments).
(D) Western analysis comparing the levels of cell death (CASP3) between normal HUF5-iPSC-derived neurons (5c2) and PDG2019S-iPSC-derived neurons (6c3)
at various H2O2 treatments and stages of neuronal differentiation.
See also Figure S4 and Table S2 for RT-PCR analysis and cell counts
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Figure 6. Effect of 6-Hydroxydopamine on DA Neurons
(A) Representations of neurodegeneration in H9-, HUF5- and G2019S-iPSC-derived neurons when treated with various concentrations of 6-OHDA. Scale bar,
50 mm.
(B) Quantification of cells double positive for TH and CASP3. Data represent mean ± SEM (n = 3 to 4 wells per clone).
(C) Quantification of TH-negative (TUJ+) neurons that are also CASP3-positive. Data represent mean ± SEM (n = 3 to 4 wells per clone).
See also Figure S5 and Table S3 for RT-PCR analysis and cell counts.
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carrying a p.G2019S mutation in LRRK2, were more vulnerable
to peroxide-induced oxidative stress than normal HUF5-iPSC-
and H9-hESC-derived neurons.Effect of 6-Hydroxydopamine on DA Neurons
Mitochondrial defects are also implicated in PD. 6-Hydoxydop-
mine (6-OHDA) can directly lead to destruction of DA neurons
by formation of free radicals and/or by inhibition of mitochondrial
complexes I and IV (Berretta et al., 2005; Ding et al., 2004; Sauer
and Oertel, 1994). To test and to compare effects of 6-OHDA on
H9-, HUF5-, and G2019S-iPSC derived DA neurons, we treated
35 day neurons with various concentrations of 6-OHDA and
assayed for cell death using methods described above (Figures
6A and 6B; Table S3). Analysis based on two-way ANOVA at
1 mM treatment showed that clones with the G2019S genotype
displayed increased (3- to 4-fold) cell death relative to control
clones from HUF5 (p < 0.05, n = 3 wells per clone). At 10 mM
treatment, all clones from G2019S showed significantly higher
(3- to 5-fold) cell death than all clones from HUF5-iPSC- and
H9-derived DA neurons (p < 0.05, n = 4 well per clone).
In contrast, in the absence of treatment, there was no difference
between all lines tested (n = 3 per clone). However, we could not
rule out the possibility that there might be differential expression
of dopamine transporter in the DA neurons between these lines.
We also compared levels of cell death in TH-negative cell popu-
lations and observed only a slight increase in percentage ofTH-negative neurons that colabeled with CASP3 with increasing
concentrations of 6-OHDA (Figure 6C); however, there was no
detectable differences between disease and wild-type lines
(n = 3 to 4 wells per clone or per line at each concentration).
These findings suggest that G2019S-iPSC-derived DA neurons
were more sensitive to 6-OHDA than both HUF5-iPSC- and
H9-derived DA neurons.
RT-PCR analysis of neurons after 10 mM of 6-OHDA treatment
showed differential gene expression patterns between lines
(Figure S5). Results showed that ALDH1A1, HMOX1, MSX2,
NEFL, SNCG, LRRK2, and EN2 expression levels were lower in
G2019S line than H9 and HUF5 lines. However, significant differ-
ences (p < 0.05, n = 3 per clone) were not uniform across all
clones of the same genotype, suggesting that there was clonal
variability between lines.Effect of MG-132 on DA Neurons
Finally, we tested for sensitivity to impaired protein degradation
using the proteasome inhibitor MG-132, which has been shown
to cause DA neuron degeneration both in vitro and in an animal
model (Sun et al., 2006), on iPSC-derived neurons (Figures 7A
and 7B; Table S4). G2019S-iPSC-derived DA neurons treated
with 10 mM of MG-132 showed a higher number of TH-positive
cells that are also CASP3-positive than unaffected H9 and
HUF5 (p < 0.05, n = 2 to 3 wells per clone). When we compared
MG-132 toxicity directly with 200 uM H2O2 treatment, the
effect was similar. In addition, TH-negative cells showed lessCell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 275
Figure 7. Effect of ROCK Inhibitor, Y-27632, on Patient-Derived DA Neurons
(A) Representations of neurodegeneration in H9-, HUF5- and G2019S-iPSC derived neurons when treated with neurotoxins, H2O2 and MG-132, and ROCK
inhibitor Y-27632. Scale bar, 50 mm.
(B) Quantification of cells double positive for TH and CASP3. Data represent mean ± SEM (n = 2 to 3 wells per iPSC clone; average of three clones of HUF5 and
two clones of G2019S).
(C) Quantification of TH-negative (TUJ+) neurons also positive for CASP3 after treatments as described above. Data represent mean ± SEM (n = 2 to 3 wells per
clone).
See also Table S4 for cell counts.
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iPSC-Derived Neurons Model Parkinson’s Diseasecaspase-3 activation than TH-positive cells in the presence of
MG-132 (Figure 7C). Taken together, G2019S-iPSC-derived
DA neurons demonstrated increased susceptibility to H2O2,
6-OHDA, and MG-132, relative to DA neurons derived from
pluripotent cell lines carrying wild-type LRRK2.
Effect of ROCK Inhibitor, Y-27632, on Patient-Derived
DA Neurons
West and colleagues have shown that the G2019S mutation
increases LRRK2 kinase activity and that expression of
a LRRK2 G2019S transgene increases susceptibility to
peroxide-induced cell death (Cookson, 2009; West et al.,
2005). They also showed that mutations that abolish kinase
activity of the LRRK2 transgene also abolished the increase in
peroxide-induced cell death. Subsequent work from Nichols
and colleagues further showed that several ROCK inhibitors
are able to effectively reduce kinase activity of a recombinant
G2019S LRRK2 protein in cell-free systems (Nichols et al.,
2009). Among these were ROCK inhibitor, Y-27632, which dis-
played selective inhibition of mutant LRRK2 over wild-type
LRRK2 using in vitro assays. The prediction from this work was
that inhibition of LRRK2 kinase activity might attenuate the
LRRK2 G2091S-mediated increase in neuron vulnerability.
To test this prediction, 35 day neurons were exposed to H2O2
orMG-132 for 48 hr in the presence or absence of Y-27632. Cells
were then fixed and stained for Tuj1, TH, and CASP3 (Figures 7A
and 7B; Table S4). Differential sensitivity of TH-positive neurons
from the LRRK2 G2019S genetic background was then276 Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc.observed following H2O2 or MG-132; however, we noted that
Y-27632 had no measurable effect following exposure to
peroxide and instead appeared to exacerbate cell death
following treatment with MG-132. These data suggested that
inhibition of kinase activity with ROCK inhibitor Y-27632 does
not protect patient-derived DA neurons from H2O2- or
MG-132-mediated caspase-3 activation.
DISCUSSION
Parkinson’s disease is a devastating disease that affects both
motor and nonmotor functions. A defining feature of PD is
progressive loss of mDA neurons, yet the underlying etiology
of most PD is completely unknown. Studies from animal and
cellular models have shown that certain mutations in the
LRRK2 gene locus can increase its kinase activity, which
contributes to neurotoxicity, possibly via oxidative stress path-
ways (Heo et al., 2010; MacLeod et al., 2006; Smith et al.,
2006; West et al., 2005). Moreover, cells expressing mutant
LRRK2 have been shown to be more vulnerable to peroxide-
induced cell death than LRRK2 wild-type cells (Cookson, 2009;
West et al., 2005). Although the function of LRRK2 is currently
not resolved, reduced expression of LRRK2 mRNA limits neural
progenitor cell differentiation potential toward dopaminergic
neurons and may enhance cell death (Milosevic et al., 2009).
These findings suggest that LRRK2 plays a pivotal role in
neuronal survival, and disruption in this gene can lead to PD
(Lin et al., 2009).
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iPSC-Derived Neurons Model Parkinson’s DiseaseHere, we observed a subset of cardinal PD features in DA
neurons derived from a patient with symptomatic PD possessing
the LRRK2 p.G2019Smutation. Though this study was limited to
a single PD-iPSC line, with multiple subclones and controls,
methods and results described should facilitate direct compari-
sons between lines carrying different LRRK2 mutations or
carrying different mutations that predispose to PD. Most impor-
tantly, cardinal features that we observed included differential
accumulation of a-synuclein protein, upregulation of key oxida-
tive stress response genes, and vulnerability of PD neurons to
neurotoxins, including H2O2, MG-132, and 6-OHDA, relative to
unaffected neurons. Although differences are modest, given
the more limited duration of experiments in vitro (relative to the
time course of disease in humans), the distinction between
TH-positive and -negative neurons and the increased suscepti-
bility of diseased DA neurons from the p.G2019S LRRK2 patient
suggest that central characteristics of PD are retained and
detected in this model system. We believe that the differential
effect would be more dramatic between the normal control and
the diseased neurons if we could allow neurons to mature longer
in culture. However, it is difficult to maintain DA neurons in
culture, based on our modified protocol, for an extended period
of time (50+ days) because cells tend to detach and die
spontaneously.
West et al. (2005) have shown that LRRK2 kinase activity is
elevated by the G2019S mutation, leading many to speculate
that either increased kinase activity or altered kinase target
spectrum may underlie LRRK2-related PD (Cookson, 2009).
Nichols et al. (2009) further identified ROCK inhibitors, including
Y-27632, that were able to effectively reduce kinase activity of
recombinant LRRK2 G2019S. Contrary to our expectations,
Y-27632, had no protective effect on patient-derived G2019S
LRRK2 DA neurons. This could be due to different systems
and methods used in our studies. We used hESC- and iPSC-
derived DA neurons, whereas Nichols et al. used a cell-free
system.
Based on our findings, we propose that G2019S-iPSC derived
neurons are more vulnerable to perturbation, caused by oxida-
tive stress, mitochondrial impairment, or defects in protein
degradation. This vulnerability was selective for TH-positive
neurons and accompanied by elevated a-synuclein content
and a steady-state elevation in expression of several stress-
response genes, including activation of CASP3. In spite of the
potential usefulness of using iPSC-derived neurons described
here, however, there are a number of limitations that must be
addressed. First, it is currently not possible to obtain a large
number of DA neurons that are pure of contamination of other
cell types. This means that results must be interpreted by
a combination of experimental means to validate each data
point, thus making high-throughput approaches difficult.
Second, there is limited knowledge at this time of the endo-
genous programs and markers of human DA neurons, especially
those with specific regionalization. Third, there is limited know-
ledge of the impacts of specific genetic and environmental
parameters individually or in combination that trigger the onset
of neurodegeneration. In spite of these limitations, the human
iPSC system may provide a system that can be used to address
specific hypotheses, especially regarding the onset of PD in
those with genetic determinants. Subsequently, results may beextended from genetically defined PD to a further understanding
of the ontogeny and molecular mechanisms underlying sporadic
PD and possibly other neurological disorders that may share
a similar etiology.EXPERIMENTAL PROCEDURES
Isolation of Primary Human Skin Fibroblasts and Generation
of iPSCs
Methods for isolation and culture of primary adult human fibroblasts, stem cell
culturing, retroviral production, and infection were as described (Byrne et al.,
2009). HUF5 cells were obtained from a 46-year-old healthy female, and
HUF6 (G2019S) cells were obtained from a 60-year-old female PD patient.
Procedures for generation of iPSCs were adapted from Yamanaka and
colleagues (Takahashi et al., 2007). Briefly, 1 day before transduction,
fibroblasts were seeded at 8 3 104 cells per well of a 6-well plate. Equal
volumes (0.5 ml) of each of the four or three (without CMYC) concentrated viral
supernatant, supplemented with 8 mg/ml polyprene, were mixed to obtain
a final concentration of 103 and added to growing fibroblasts. Next day, viral
supernatants were washed with PBS and replaced with fresh MEF medium.
The same infection process was repeated a day later. Five days post-trans-
duction, cells were detached with trypsin, resuspended in MEF medium,
counted, and seeded at 5 to 10 3 104 cells onto 10 cm dishes preplated
with irradiated MEFs. After overnight incubation, MEF medium was replaced
with hESC medium, and thereafter, medium was changed every other day or
every day, as required. hESC-like colonies appeared among background colo-
nies around 14–20 days (for four factors) or 50–55 days (for three factors) post-
transduction. Colonies were manually picked and transferred to 12- or 24-well
plates preplated with CF1 feeders for expansion. HUF5-iPSCs were derived
with four factors, and G2019S-iPSCs were derived with three factors without
CMYC. For enzymatic passaging, iPSCs were incubated with 200 U/ml colla-
genase IV (Invitrogen) at 37C for 3–5 min, washed with PBS and then culture
medium, and scraped off the dish with a cell scraper. Colonies were further
dissociated by pipetting, centrifuged, split at a 1:5 ratio, and transferred to
a new dish precoated with irradiated embryonic mouse feeders (CF1, Charles
River). For manual passaging, individual colonies were simultaneously cut and
scraped off from the plate using a customized hockey-style (half-loop) glass
pipette tip and then transferred to a new dish.Alkaline Phosphatase Staining and Immunocytochemistry
AP staining was done using the Vector Red Alkaline Phosphatase Substrate Kit
I (Vector Laboratories, CA), according to the manufacturer’s protocol.
Standard immunostaining techniques were applied for surface, cytoplasmic,
and nuclear protein localization as described (Byrne et al., 2009). Primary
antibodies and dilutions were as follows: OCT4 (1:100), nestin (1:100),
NURR1 (1:100), and FOXA2 (1:50) were obtained from Santa Cruz Biotech-
nology; SOX2 (1:200), SSEA1 (1:200), SSEA4 (1:200), TRA1-60 (1:200),
TRA1-81 (1:200), STELLA (1:200), and LRRK2 (1:200) were obtained fromMilli-
pore; NANOG (1:100), b-III-tubulin (TUJ1, 1:200), a-smooth muscle actin
(1:200), PITX3 (1:200), OTX2 (1:200), CALB (1:200), sheep tyrosine hydroxylase
(1:400), and vimentin (1:200) were obtained from Abcam; desmin (1:200) was
obtained from Lab Vision; rabbit tyrosine hydroxylase (1:400) was obtained
from Pel-freez; a-fetoprotein (1:200) and VASA (1:200) were obtained from
R&D Systems; cleaved caspase-3 (1:400) was obtained from Cell Signaling;
and synaptotagmin-1 (1:50) was obtained from Dr. T. Sudhof, Stanford
University.Western Blotting Analysis
Proteins were extracted from the cells by RIPA buffer (Sigma)/Protease inhib-
itor (Roche) mixture, measured using the BCA Protein Assay Kit (Thermo
Scientific), separated by running in 15% SDS-PAGE gel, and transferred to
a PVDF membrane (Millipore). Signals were detected by ECL Plus Western
Blotting Detection Kit (GE Healthcare) and analyzed by NIH ImageJ. Primary
antibodies and their dilutions were used as follows: a-synuclein (1:1000,
Thermo Scientific), cleaved caspase-3 (1:1000, Cell Signaling), GAPDH
(1:10,000, Abcam), TH, and PITX3 (1:1000, Abcam). We note that previousCell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc. 277
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vated caspase-3 (Duan et al., 2003).
Neuronal and Spontaneous Differentiation
Directed differentiation of iPSCs into midbrain dopaminergic neurons was
previously described (Chambers et al., 2009) with some adjustments. Briefly,
stem cells were plated onto 6-well plates precoated with 2.5% Matrigel
(BD Biosciences) and allowed to reach 80% confluent in standard hESC
medium. Prior to neural induction, differentiated cells were manually cleared.
For the first 5 days, cells were treated with SB431542 (10 uM; Tocris Biosci-
ence) and Noggin (100 ng/ml) in serum placement medium (standard hESC
medium without FGF2); for the next 4 days, cells were treated with human
recombinant Sonic hedgehog (200 ng/ml) in DMEM:F12 (Invitrogen) and N2
supplement (Invitrogen); and for the next 3 days, cells were switched to
BDNF (20 ng/ml), ascorbic acid (200 uM, Sigma-Alderich), sonic hedgehog
(200 ng/ml), and FGF8b (100 ng/ml) in DMEM:F12/N2. Thereafter, cells were
treated with DMEM:F12/N2 with BDNF, ascorbic acid, GDNF (10 ng/ml),
TGF-b (1 ng/ml), and cAMP (500 uM, Sigma-Aldrich). Note that we did not
separate stem cells into single cells and avoided using Rho kinase (ROCK)
inhibitor during the process of differentiation. All growth factors were
purchased from R&D Biosystems. Initially, neurons were passed onto fresh
plates after 15 days of induction and passed again when the culture expanded.
The purity of neurons was improved with each round of collagenase treatment
and passaging. Large neuronal clumps (or neurospheres) were manually
dissected into smaller pieces with the aid of collagenase treatment.
For spontaneous embryoid body (EB) differentiation, iPSCs were seeded
into ultra low attachment hydrogel (Corning) plates containing DMEM:F12 sup-
plemented with 20% FBS (HyClone), 2 mM L-glutamine, 0.1 mM nonessential
amino acids, and 0.1 mM 2-mercaptoethanol differentiation medium. After
8 days growing in the suspension, the EBs were transferred to gelatin-coated
dishes containing the same medium to allows the cells to expand for an
additional 10–25 days.
Neurotoxicity Assays and ROCK Inhibitor Assays
Starting at 15–30 days postneuronal differentiation, neurons were purified
several rounds by enzymatic (Collagenase IV treatment) and manual (hand-
dissected) passaging. When the majority of the cells were of neuronal pheno-
type, neurons were manually and randomly picked and transferred to 48-well
culture plates precoated with matrigel. Five neuronal clumps (neurospheres)
were transferred into each well and maintained with DMEM:F12/N2 medium
containing BDNF, GDNF, cAMP, TGFb, and Ascorbic Acid. Prior to transfer,
large neurospheres were delicately dissected to smaller pieces. One day prior
to neurotoxin treatment, before day 35 postdifferentiation, medium with
growth factor was replaced with DMEM:F12/N2 medium alone. Neurospheres
that barely adhered to the well substrate were washed out at this step. For
H2O2 assay, on day 35, fresh solution (30%, Acros) was diluted with
DMEM:F12/N2 medium alone and added to each neuronal well to reach the
desired final concentration. Without any disturbance, 24–48 hr later, cells
were fixed with 4% PFA and analyzed using immunohistochemistry. For
6-hydroxydopamine assay, fresh agent (Invitrogen) was reconstituted in Phos-
phate Buffered Saline (GIBCO) with 1mMAscorbic Acid and then diluted to the
desired final concentration with DMEM:F12/N2 medium. 6-OHDA was freshly
prepared, and the entire procedure was done in the dark. 6-OHDA was added
to the neurons at day 35 postdifferentiation. Treated cells were fixed following
48 hr of reincubation. MG-132 (Calbiochem) was dissolved in ethanol and
added to 35-day-old neurons to the final concentration of 10 mM. After
48 hr, cells were fixed in a similar manner as described above. ROCK inhibitor,
Y-27632, (Calbiochem) was diluted in water and used at a final concentration
of 10 mM. For rescue attempts, Y-27632 was mixed together with neurotoxins
and then added to 35-day-old neurons. After 48 hr, cells were fixed as above.
Cell Counting
After neurons were fixed in 48-well plates, they were immunostained for TH,
TUJ1, or CASP3 as described above. Cell nuclei were also counterstained
with DAPI. Data were collected and analyzed by a confocal microscope (Zeiss)
with a 103 objective and at 1.5 optical zoom. Fields of neurons (TH-positive)
were systematically scanned (top to bottom and left to right) and captured.
TUJ1 and CASP3 signals were not used as criteria for scanning and capturing.278 Cell Stem Cell 8, 267–280, March 4, 2011 ª2011 Elsevier Inc.Subsequently, raw images were merged with ImageJ and counted. TH-posi-
tive-cell channel in a particular field were all counted first, then CASP3-positive
channel was turned on and counted together with TH-positive-cell channel.
At least two entire random fields and up to 100 cells were counted per well.
In some cases, especially at higher toxin concentrations, the entire well was
counted because of massive cell death.
Bisulfite Sequencing
Bisulfite sequencing and analysis ofOCT4 and NANOG promoter regions was
performed as previously described (Kossack et al., 2009).
RNA Extraction and RT-PCR
Total RNA was purified using RNeasy Mini Kit (QIAGEN) according to the
manufacturer’s instructions. One microgram of RNA was used in reverse
transcription reaction (20 ml total) with Superscript III (Invitrogen) and random
hexamers. 1 ml of the cDNA products were treated with 10 ml of RT-PreAmp
master mix consisting of 5 ml Cells Direct 23 reaction mix (Invitrogen), 2.5 ml
0.23 PPP mix (48-gene set, Taqman probes), 1 ml Platinum Taq (Invitrogen),
and 1.5 ml TE Buffer (QIAGEN). Reactions were preamplified with the following
settings: one cycle at 50C, 15 min; one cycle at 70C, 2 min; and 14 cycles at
95C, 15 s and at 60C, 4 min. Reactions were diluted with TE buffer to 20 ml.
cDNA (2.25 ml) was used in downstream RT-PCR analysis via the Biomark
Fluidigm system (Fluidigm). Ct values for each sample and gene were normal-
ized in relative to GAPDH, RPLPO, CNNTB1, CENTB3, and EEF1a by qBase-
Plus (Biogazelle).
Measurements of Dopamine Release
After 60 days of neuronal differentiation, media was removed and 1 ml of N2
supplemented with 56mMKCl was added per well (6-well dish) and incubated
at 37C for 15min. This was collected and immediately frozen in liquid nitrogen
and stored at 80C until assay. Subsequently, protein lysates of each well
were made in ice cold 25 mM Tris supplemented with a Complete Mini
protease inhibitor cocktail tablet (Roche). Lysates were sonicated and cleared
by maximum speed centrifugation in a tabletop microcentrifuge. Soluble
protein concentrations were measured by a standard Bradford assay. KCl
samples were thawed, stabilized at a final concentration of 0.4N perchloric
acid, and centrifuged at 15,000 rpm at 4C for 12 min to clear debris. Super-
natant was collected and dopamine assayed by HPLC with electrochemical
detection (Coularray detector, ESA, Chelmsford, MA) using a reverse phase
C18 column (Perkin Elmer Instruments, Shelton, CT). The mobile phase
consisted of a mixture of 90 mM sodium acetate, 35 mM citric acid, 130 uM
ethylene-diamine-tetra-acetic-acid (EDTA), 230 uM 1-octanesulfonic acid
and 10% (v/v) methanol, with a flow rate of 1mL/min. DA concentration was
quantified by comparison of AUC to known standard dilutions. Well to well
variation was adjusted by protein determinations of cleared protein lysates.
Statistical Analysis
Student’s two-tailed t test was used to determine statistical significance for
data generated from qRT-PCR. For western blot and cell counting, statistic
analysis was performed using a one-way and two-way ANOVA, respectively,
each with Duncan’s multiple range post-hoc tests. For H2O2 toxicity assay,
the experiment was repeated twice with multiple biological replicates. Differ-
ences were considered significant at p < 0.05.
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